针对阿尔茨海默氏症的Aβ向的synNotch受体:扩大对细胞外蛋白质聚合物的应用
bioRxiv : the preprint server for biology
|October 28, 2024
概括
合成Notch (synNotch) 受体现在可以在阿尔茨海默病研究中准细胞外蛋白质聚合物,如粉样β. 这种工程系统在对这些聚合物的反应中产生治疗性抗体.
科学领域:
- 生物技术是生物技术.
- 神经科学是一个神经科学.
- 分子生物学分子生物学
背景情况:
- 合成的Notch (synNotch) 受体系统能够在响应细胞外信号时实现向基因转录.
- 由于特定的激活需求,目前的synNotch应用程序仅限于膜绑定目标.
- 在阿尔茨海默氏症 (AD) 中,synNotch针对细胞外蛋白质聚合物的潜力,例如粉样β (Aβ) 在阿尔茨海默氏症 (AD) 中,仍然未被探索.
研究的目的:
- 设计和验证一种能够准细胞外粉样蛋白β (Aβ) 聚合物的synNotch受体.
- 评估设计的synNotch系统诱导AD向抗体的产生的能力.
主要方法:
- 设计了一个针对Aβ的synNotch受体.
- 设计了synNotch系统来控制仿制Lecanemab或Aducanumab抗体的产生.
- 使用NIH 3T3细胞表达synNotch系统用于检测和响应试验.
主要成果:
- NIH 3T3细胞表达了工程化synNotch受体,成功检测出细胞外Aβ聚合物.
- 合成系统对Aβ聚合物作出反应,通过合成和分泌仿制品阿杜卡努马布或莱卡内马布.
- 通过synNotch系统证明了细胞外蛋白质聚合物的成功向.
结论:
- 该研究成功地扩展了synNotch技术的应用范围,超出了膜绑定的目标.
- 设计的synNotch系统可以准像Aβ这样的细胞外蛋白聚合物,为AD研究开辟新的途径.
- 这一进步为研究神经退行性疾病和蛋白质聚合物向提供了显著的好处.
更多相关视频
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.3K
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
6.7K
相关概念视频
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
03:03Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
01:26Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449